Yap, T. A., Hernando-Calvo, A. H., Calvo, E., Moreno, V., Marquez, R., Papadopoulos, K. P., Corbacho, J. G. G. -., Guerrero, T. H., Spira, A. I., Tan, D. S. P., Ottensmeier, C. H., Koseoglu, S., Chang, P. K., Zhang, E., Martinez, J. L., Trück, C., Magenheim, R., Celik, I., Türeci, Ã., Åžahin, U. (2025). First-in-human phase I/II trial evaluating BNT142, a first-in-class mRNA encoded, bispecific antibody targeting Claudin 6 (CLDN6) and CD3, in patients (pts) with CLDN6-positive advanced solid tumors.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.2501